- Patent Title: Repurposing anti-androgen therapy for COVID-19 and immunotherapy
-
Application No.: US17692376Application Date: 2022-03-11
-
Publication No.: US12076312B2Publication Date: 2024-09-03
- Inventor: Gopal Iyer , Albert Wang
- Applicant: Wisconsin Alumni Research Foundation
- Applicant Address: US WI Madison
- Assignee: Wisconsin Alumni Research Foundation
- Current Assignee: Wisconsin Alumni Research Foundation
- Current Assignee Address: US WI Madison
- Agency: Boyle Fredrickson, S.C.
- Main IPC: A61K31/4166
- IPC: A61K31/4166 ; A61K31/167 ; A61K31/277 ; A61K31/4155 ; A61K31/4439 ; A61P37/06
Abstract:
Use of an AR antagonist, e.g., enzalutamide and other known AR antagonists, for reducing inflammatory genes of COVID-19 subjects is provided by the present invention. In other aspects, the present invention is directed to the use of an AR antagonist, e.g., the drug enzalutamide and other known AR antagonists, to treat lung cancer in a subject. In yet other aspects, the present invention is directed to an AR antagonist, e.g., the drug enzalutamide and other known AR antagonists, as an immunotherapy.
Public/Granted literature
- US20220288029A1 Repurposing Anti-Androgen Therapy for COVID-19 and Immunotherapy Public/Granted day:2022-09-15
Information query
IPC分类:
